Brief: Shanghai Henlius Biotech Enters License Agreement With Sandoz For Hlx13
29/04/2025 11:11
April 29 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: ENTERS LICENSE AGREEMENT WITH SANDOZ FOR HLX13 SANDOZ GRANTED EXCLUSIVE RIGHTS TO COMMERCIALIZE HLX13 IN MULTIPLE REGIONS SANDOZ TO PAY HENLIUS $31 MILLION UPFRONT TO RECEIVE UP TO $270 MILLION IN MILESTONE PAYMENTS Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln